Skip to content

Dr. Gearóid Tuohy

Healthcare economics study finds that aflibercept and ranibizumab are not cost effective in the treatment of diabetic macular edema.

Research, conducted by the Diabetic Retinopathy Clinical Research Network (DRCRN), suggests that aflibercept (2.0mg) and ranibizumab (0.3mg) are not cost effective when compared to bevacizumab… Read More »Healthcare economics study finds that aflibercept and ranibizumab are not cost effective in the treatment of diabetic macular edema.